Evidence map›Paper›PMID 41157586›Full record

ArticleViruses2025

SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes.

Yanjing Peng, Panjian Wei, Meng Gu, Guirong Wang, Teng Ma, Jinjing Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanjing PengCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
Panjian WeiDepartment of Laboratory Medicine, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
Meng GuCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
Guirong WangDepartment of Laboratory Medicine, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
Teng MaCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
Jinjing TanCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.ORCID 0000-0003-3534-8376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic prompted investigation into the interaction between SARS-CoV-2 infection and immune checkpoint inhibitor (ICI) therapy in lung cancer patients. Understanding this interplay is crucial for optimizing cancer immunotherapy.

methodsA retrospective analysis was conducted on lung cancer patients, characterizing changes in peripheral immune cells and plasma cytokines (including IL-10 and IL-12p70) before, during, and after SARS-CoV-2 infection. Progression-free survival (PFS) was compared between ICI-treated patients with and without COVID-19. Cytokine dynamics were further analyzed in a non-infected cohort.

resultsSARS-CoV-2 infection induced a prolonged systemic cytokine storm, with elevated IL-10 and IL-12p70 levels and reduced monocyte proportions lasting up to 10 weeks post-recovery. Despite this immune perturbation, COVID-19 did not impair long-term PFS; instead, a transient improvement in disease control was observed in infected patients. In non-infected patients, sustained or increased IL-10 and IL-12p70 levels during ICI therapy were associated with longer PFS (

conclusionsSARS-CoV-2 infection transiently alters the immune landscape in lung cancer patients without compromising ICI efficacy. The sustained elevation of IL-10 and IL-12p70 may contribute to short-term clinical benefits. Monitoring cytokine dynamics could serve as a prognostic tool for predicting ICI response.

Indexed as

COVID-19Lung NeoplasmsTumor MicroenvironmentAgedAged, 80 and overCytokine Release SyndromeCytokinesFemaleHumansImmune Checkpoint InhibitorsImmunotherapyInterleukin-10Interleukin-12MaleMiddle AgedRetrospective StudiesCytokinesImmune Checkpoint InhibitorsInterleukin-10Interleukin-12COVID-19 and lung cancercytokine dynamicsImmune Checkpoint Inhibitors (ICI)immune landscape alterationProgression-Free Survival (PFS)

Identifiers

PMID41157586
PMCPMC12568021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.